Skip to main content

Table 1 Baseline characteristics of included 451 patients with HCC and comparison of factors between patients with and without severe PHLF

From: Impact of aspartate aminotransferase–to–platelet ratio index based score to assess posthepatectomy liver failure in patients with hepatocellular carcninoma

Variables All patients (n = 451) Severe PHLF P value
No (n = 421) Yes (n = 30)
Age (years) 71 (35–91) 71 (35–91) 68 (35–82) 0.2788
Sex, female/male/female 146/305 139/282 7/23 0.2734
BMI (kg/m2) 23.2 (13.4–34.1) 23.3 (13.4–34.1) 21.6 (19.2–29.0) 0.0237*
Etiology
HBV/HCV/HBV + HCV/NBNC
65/280/5/101 59/259/5/98 6/21/0/3 0.3103
Albumin (g/dL) 4.0 (2.5–5.1) 4.0 (2.5–5.1) 3.7 (3.0–4.9) 0.0054*
Total bilirubin (mg/dL) 0.7 (0.2–2.0) 0.7 (0.2–2.0) 1.0 (0.4–1.9) 0.0012*
AST (IU/L) 37 (8–252) 36 (8–252) 55 (32–150) < 0.0001**
ALT (IU/L) 34 (6–312) 33 (6–312) 47 (20–245) 0.0004**
Platelet count (× 109/L) 134 (24–660) 139 (24–530) 89 (33–660) 0.0019*
PT (%) 91.5 (46.3–130.3) 91.9 (46.3–130.3) 82.3 (49.2–107.9) 0.0019*
INR 1.06 (0.88–1.67) 1.05 (0.88–1.67) 1.11 (0.97–1.56) 0.0023*
Creatinine (mg/dL) 0.76 (0.20–7.11) 0.76 (0.2–7.11) 0.84 (0.5–6.0) 0.0152*
Urine nitrogen (mg/dL) 14.8 (5.3–48.9) 14.8 (5.3–48.9) 14.7 (9.3–47.5) 0.6681
ICG-R15 (%) 16.8 (0.9–67.0) 16.5 (0.9–67.0) 24.0 (3.9–54.6) 0.0068*
PALBI − 2.66 (− 3.43 to − 1.31) − 2.67 (− 3.43 to − 1.65) (− 2.45 (− 3.14 to (− 1.31) 0.0055*
APRI 0.96 (0.09–12.7) 0.91 (0.09–12.7) 2.16 (0.19–8.99) < 0.0001**
FIB-4 index 3.3 (0.5–100.6) 3.2 (0.5–100.6) 6.5 (0.7–22.2) < 0.0001**
ALPlat index 500 (322–975) 504 (322–932) 466 (331–975) 0.0016*
MELD 7.3 (6.4–15.5) 7.3 (6.4–15.1) 8.9 (6.4–15.5) 0.0005**
Child-Pugh grade A/B 438/13 410/11 28/2 0.1998
Blood loss (mL) 270 (0–3330) 260 (0–2800) 695 (33–3330) 0.0003**
Operating time (min) 214 (60–633) 212 (60–630) 276 (90–633) 0.0014*
Extent of hepatectomy
Minor/major
406/45 384/37 22/8 0.0016*
AFP (ng/mL) 11.7 (1.0–93721) 11.2 (1.0–46262.6) 39.3 (2.1–93721) 0.0014*
DCP (mAU/mL) 24 (0.01–109830) 24 (0.01–43253) 42 (0.03–109830) 0.1851
BCLC grading
0/A/B
109/261/81 105/245/71 4/16/10 0.0522
TNM staging
I–II/III–IV
213/238 206/215 7/23 0.0114*
Tumor size (cm) 2.4 (0.5–13.0) 2.3 (0.5–13.0) 3.0 (1.5–12.0) 0.0069*
Solitary/multiple 326/125 309/112 17/13 0.0479*
Poorly differentiation 114 (25.3%) 105 (24.9%) 9 (30.0%) 0.5379
Microscopic vascular invasion 35 (7.8%) 34 (8.1%) 1 (3.3%) 0.3482
Microscopic intrahepatic metastasis 63 (14.0) 55 (13.1%) 8 (26.7%) 0.0379*
Liver cirrhosis (F4) 206 (45.7%) 187 (44.4%) 19 (63.3%) 0.0445*
  1. Data are presented as N or median (range). AFP alpha-fetoprotein, ALPlat index platelet count + 90 × albumin, ALT alanine aminotransferase, APRI AST-to-platelet ratio index, AST asparate aminotransferase, BCLC Barcelona Clinic Liver Cancer, BMI body mass index, CRP C-reactive protein, DCP des-γ-carboxyprothrombin, FIB-4 fibrosis-4, HBV hepatitis B virus, HCV hepatitis C virus, ICG-R15 indocyanine green dye retention rate at 15 min, MELD model for end-stage liver disease, PALBI platelet-albumin-bilirubin, PHLF posthepatectomy liver failure, PT prothrombin time, TNM tumor, node, metastasis *P < 0.05 and **P < 0.001